FLASH is the largest prospective interventional registry of PE evaluating patient outcomes after treatment with the FlowTriever system.
Outcomes for the Full US Cohort of the FLASH Registry
Data Presented by Catalin Toma, MD at TCT September 2022
Real World Patients
85%
Intermediate-high or high-risk patients
32%
Lytics Contraindication
65%
Concomitant DVT
Immediate Hemodynamic Improvement
*In patients with cardiac index <2.0 L/min/m2 at baseline
Excellent Safety Results and 30-day Mortality Outcomes
1.8%
Major Adverse Events (MAEs)
at 48-hours
0
Device Related Deaths
Indications:
The FlowTriever System is indicated for the (1) non-surgical removal of emboli and thrombi from blood vessels, (2) Injection, infusion and/or aspiration of contrast media and other fluids into or from a blood vessel.
The FlowTriever System is intended for use in the peripheral vasculature and for the treatment of pulmonary embolism. The Triever Catheters are intended for use in peripheral vasculature and for the treatment of pulmonary embolism
Triever Catheters are also intended for use in treating clot in transit in the right atrium
The FlowTriever2 Catheter is indicated for: the non-surgical removal of emboli and thrombi from peripheral blood vessels. Injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel.
The FlowTriever2 Catheter is intended for use in the peripheral vasculature.
The FlowSaver Blood Filter is used with Triever Catheters for autologous blood transfusion.
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician
See Instructions for Use for complete Indications for Use, contraindications, warnings, and precautions.